logo
Nannies and air hostesses accuse Mohamed al-Fayed of sexual abuse

Nannies and air hostesses accuse Mohamed al-Fayed of sexual abuse

Yahoo31-03-2025
Mohamed al-Fayed's former personal staff are seeking to sue the tycoon's estate over sexual abuse they allegedly suffered while working for the billionaire.
Law firm Leigh Day has sent pre-action letters to Mr Fayad's estate on behalf of two former air hostesses who worked for his luxury air carrier Fayair, and three of the family's former nannies.
The five women claim they suffered 'serious sexual abuse, harassment and mistreatment' while working for the Egyptian billionaire between 1995 and 2012.
The women allege they also faced verbal abuse and threats when they tried to raise concerns about the mistreatment. All of the women, whose cases have not been publicly reported before, have chosen to stay anonymous.
The group are seeking compensation for the alleged abuse, and have called for an independent public inquiry into the business mogul and his brother Salah al-Fayed, who has also been accused of abuse. Mr Fayed died in 2010.
Richard Meeran, partner at Leigh Day, said: 'We have taken this step on behalf of those of our clients who were abused by Mr Fayed while working for him or his other businesses outside of Harrods.
'Our clients took on roles as professionals and should have been able to expect a safe working environment, instead they were subjected to serious sexual abuse, harassment and mistreatment.'
The lawsuits come as Harrods, the Knightsbridge department store Mr Fayed bought in 1985, faces a string of allegations of sexual misconduct by the businessman made by former employees.
Mr Fayed, who died in 2023 aged 94, is accused of multiple counts of rape and attempted rape by women who worked at Harrods.
Allegations include claims Mr Fayed sexually assaulted a 15-year-old girl inside Harrods' boardroom. Another woman who worked as Mr Fayed's personal assistant claimed the businessman raped her in his luxury apartment that overlooked London's Hyde Park.
Mr Meeran said: 'Much of the media reporting around Mr Fayed's decades of depraved and predatory behaviour has centred around his work at Harrods, but it is important that his estate is also made legally accountable for the widespread abuse he perpetrated against those who may never have had dealings with the famous store.'
Women who worked for Mr Fayed's other ventures, including Fulham FC and the Ritz Hotel Paris, have also alleged they were sexually abused by the Egyptian billionaire.
Harrods itself, which is now owned by the Qatar Investment Authority, has said it has settled with more than 250 former employees who allege they were abused.
The Knightsbridge store has also reportedly increased the maximum amounts it is offering in compensation to ex-Harrods staff who were abused by Mr Fayed, from sums of £330,000 to £400,000, Sky News reported on Sunday.
Commenting on the new compensation scheme, a Harrods spokesperson said: 'It would be premature for us to comment on the nature and details of a scheme that is currently under consultation.
'We are actively inviting the valuable input from survivors and their legal representatives to establish the final scheme that aims to be survivor-first, trauma-informed, and fair in its approach to compensation. Further updates will be provided once the consultation period is complete.'
Lawyers for Mr Fayed's estate were contacted for comment.
Al-Fayed was born the son of a school inspector in Alexandira, Egypt in 1929. He started his career selling fizzy drinks on the streets of his home city before branching out to furniture and shipping.
The Egyptian tycoon moved to London in 1964, where he cultivated linked to British high society including the Royals.
Mr Fayed acquired Harrods for £615m in 1985. He sold it to the Qatari royal family for a reported £1.5bn in 2010.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Man dead after being hit by car during fight on Geronimo Street in Baton Rouge
Man dead after being hit by car during fight on Geronimo Street in Baton Rouge

Yahoo

timean hour ago

  • Yahoo

Man dead after being hit by car during fight on Geronimo Street in Baton Rouge

BATON ROUGE, La. (Louisiana First) — The Baton Rouge Police Department is investigating after a man died in a fight on Friday. Officers responded to the 3300 block of Geronimo Street after a man was hit by a car. According to BRPD, Montrell Green, 35, and another man were involved in an argument that led to Green firing a weapon. Police said the other man got into a vehicle. While trying to escape, they hit Green as he tried to block the way out. Green was taken to the hospital but died from his injuries on Aug. 2. Police said the driver was detained for questioning and later released. No charges were announced. The investigation is ongoing, and police ask anyone with information to contact the Violent Crimes Unit at 225-389-4869 or call Crime Stoppers at 225-344-7867. Latest News See the LSU men's basketball SEC schedule for 2026 Registering to vote in East Baton Rouge Parish before 2025 fall elections: What to know MLB is calling up its first female umpire, Jen Pawol Ex-Trump surgeon general: RFK Jr. vaccine move 'going to cost lives' Chikungunya virus in China: What to know Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword

Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions
Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions

Yahoo

timean hour ago

  • Yahoo

Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions

Former FDA Director David Feigal joins Keyron as Head of Regulatory Affairs Dr Joyce Peetermans (ex-Boston Scientific) joins as Acting CTO Christopher Rowland (ex-Boston Scientific) appointed Chairman ForePass aims to replicate metabolic surgery without incisions Preparing for First-In-Human trials after strong large-animal data Head-to-head data showing superiority over $28B/year drug to be published soon LONDON & BOSTON, August 06, 2025--(BUSINESS WIRE)--Keyron, a pioneer in medical devices for advanced metabolic disease, today announced the appointment of three world-class leaders to its board of directors—including the former Director of the FDA's Center for Devices and Radiological Health (CDRH) and senior medtech industry leaders with key roles in notable exits within the endoscopy medical device sector. These appointments strengthen Keyron's regulatory, clinical, and strategic leadership as the company prepares for its upcoming clinical trials, associated global regulatory submissions, and future strategic alliances, centered around its ForePass device. ForePass is designed to replicate the outcomes of metabolic surgery—without cutting, puncturing, or trauma—through a fully reversible, minimally invasive procedure. Board Appointments David Feigal MD (Head of Regulatory Affairs) – Former Director of the FDA's Center for Devices and Radiological Health (CDRH). Covered the highest role and authority in medical devices at the FDA. Brings decades of experience guiding breakthrough technologies through FDA approval and will now be the Company's lead for FDA engagement and IDE submission. Founder of leading U.S. regulatory consultancy, NDA Partners. Widely recognized as one of the most experienced regulatory experts in the U.S., he has held senior global roles at public companies Amgen and Elan and led or advised over 20 successful medical product approvals across therapeutic areas. Joyce Peetermans, Ph.D. (Acting CTO) – 35+ years of leadership roles in R&D, Clinical Research, and Innovation in Gastroenterological and Surgical Endoscopy, and other specialties. She spent 25 years at Boston Scientific, where she was on the Endoscopy Management Board as VP of Global Clinical Programs, and VP of Innovation and Research during the $615M acquisition of Apollo Endosurgery and several other key acquisitions by Boston Scientific Endoscopy. Christopher Rowland (Chairman) – A seasoned executive with over 35 years leading Class III endoscopic and metabolic device companies. He served as President at Given Imaging prior to its $860M PillCam exit to Covidien (Medtronic) and was CEO of Neotract before its $1.1B acquisition by Teleflex. He also spent 17 years in senior roles at Boston Scientific. Christopher will chair Keyron's board of directors and support its corporate development and fundraising strategy. This leadership expansion follows several successful large-animal studies of ForePass demonstrating excellent safety, tolerability, and strong efficacy on both weight and insulin production. Key results were published in Gut (Angelini G, Galvao Neto M, Boskoski I, et al., 2024), showing ForePass's ability to replicate surgery-like results without incisions. The company is now preparing to unveil best-in-class preclinical data showing clear superiority over Semaglutide—the $28B/year standard of care for obesity and diabetes in Ozempic and Wegovy—across all major endpoints. These data are expected to be published this summer. 92% of Semaglutide patients fail to achieve 15% total body weight loss (New England Journal of Medicine, 2021; 385(6):503–515), with 85% discontinuing GLP-1 therapy within just 24 months (Reuters, 10 July 2024). Yet patients with severe obesity (BMI ≥35)—especially those who also have type 2 diabetes—need around 30% weight loss. Since GLP-1s fall substantially short and most stop taking them, surgery remains the only viable option, regularly delivering over 30% weight loss despite its risks and complications. ForePass is a fully removable, endoscopically implantable device aiming to replicate the metabolic benefits of surgery without incisions. It targets patients with BMI ≥35 and diabetes or BMI ≥40—a large, high-risk population underserved by current treatments. Giorgio Castagneto Gissey, Founder & CEO of Keyron, said: "Christopher, David, and Joyce are absolute world-class leaders. Their decision to join Keyron reflects the urgency of the metabolic crisis—especially the unmet need in diabetes and higher BMI—and the unique power of what we've built. Their expertise will be transformative as we enter human trials and deliver the first truly effective, scalable alternative to surgery for millions." Keyron, a VC-backed startup, has developed a proprietary biometabolic implant and endoscopic delivery system, secured leading clinical sites in the U.S. and internationally, and completed long-term preclinical validation. Full efficacy results—including head-to-head data versus Semaglutide in a porcine model—will be published shortly. The company is now preparing for its First-In-Human study. About Keyron Keyron is the first biometabolic device platform company, pioneering a new class of implantable therapies that aim to replicate the effects of bariatric and metabolic surgery without incisions—and restore metabolic health at its root without driving insulin overproduction or dependency. Headquartered in London and Boston, Keyron's mission is to deliver a scalable alternative to surgery—and a better option for patients with severe obesity and diabetes. See for more information. View source version on Contacts Media Contact Keyron Press Officepress@ London, UK and Boston, MA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Next court date set for Denham Springs man accused in deadly hit-and-run
Next court date set for Denham Springs man accused in deadly hit-and-run

Yahoo

timean hour ago

  • Yahoo

Next court date set for Denham Springs man accused in deadly hit-and-run

BATON ROUGE, La. (Louisiana First) — The next court date for a Denham Springs man accused of a hit-and-run that left a 20-year-old woman dead is set for October. Brandon Chenevert, 30, is accused of hitting Jody Mann on Louisiana Highway 1023 as she was walking to a friend's house. He was charged with negligent homicide, felony hit-and-run, failure to seek assistance, obstruction of justice, among other charges. Mann was hospitalized in critical condition before dying from her injuries weeks later. Chenevert is scheduled to return to court on Oct. 20 after discoveries for his Aug. 4 court appearance were not completed. Man dead after being hit by car during fight in Baton Rouge Latest News See the LSU men's basketball SEC schedule for 2026 Registering to vote in East Baton Rouge Parish before 2025 fall elections: What to know MLB is calling up its first female umpire, Jen Pawol Ex-Trump surgeon general: RFK Jr. vaccine move 'going to cost lives' Chikungunya virus in China: What to know Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store